J. Goldman & CO LP Tarsus Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 130,195 shares of TARS stock, worth $5.79 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
130,195
Previous 557,500
76.65%
Holding current value
$5.79 Million
Previous $18.3 Million
60.69%
% of portfolio
0.2%
Previous 0.57%
Shares
13 transactions
Others Institutions Holding TARS
# of Institutions
201Shares Held
40.5MCall Options Held
72.7KPut Options Held
313K-
Black Rock Inc. New York, NY3.27MShares$145 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.24MShares$144 Million2.92% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.53MShares$113 Million5.35% of portfolio
-
Jennison Associates LLC2.5MShares$111 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$100 Million9.38% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.19B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...